Key statistics
On Monday, Transcode Therapeutics Inc (RNAZ:NAQ) closed at 0.3071, 42.18% above the 52 week low of 0.216 set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.35 |
---|---|
High | 0.3598 |
Low | 0.2755 |
Bid | 0.300 |
Offer | 0.32 |
Previous close | 0.3511 |
Average volume | 2.51m |
---|---|
Shares outstanding | 17.27m |
Free float | 17.26m |
P/E (TTM) | -- |
Market cap | 6.06m USD |
EPS (TTM) | -75.48 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
- TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
- TransCode Therapeutics, Inc. Announces Closing of Public Offering
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering
- TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
- TransCode Therapeutics Open Letter to Shareholders
More ▼